Ara
Toplam kayıt 4, listelenen: 1-4
Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database
(NLM (Medline), 2022)
OBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This ...
Are There Any Clues to Predict Bamboo Spine in Axial Spondyloarthritis?
(Wiley, 2020)
[No Abstract Available]
Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results
(Elsevier Science Inc, 2021)
PURPOSE: Spondyloarthritis (SpA) is a group of diseases with overlapping skeletal and extra-articular features. Acute anterior uveitis (AAU) is the most common extra-articular manifestation of SpA. The relation between AAU ...
Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?
(Springer Heidelberg, 2022)
This study aimed to compare Tuberculin Skin Test (TST) and QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) test in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients scheduled for biological and targeted synthetic ...